· Researchers state that post-vaccine syndrome is characterized by persistent immune dysregulation & issues with blood coagulation.
-
· A medium sized study in Saudi Arabia found that 29% of participants who were infected with SARS-CoV-2 developed #LongCOVID
· In a small case series, a combination of three antivirals was effective in improving symptoms in participants with Long COVID, according to a new preprint
· The Food and Drug Administration (FDA) accepted the drug application of a potential oral therapy for the prevention of #COVID19 following exposurehttps://thesicktimes.org/2025/09/09/research-updates-september-9/
· An estimated 36% of people with a documented SARS-CoV-2 infection worldwide have experienced #LongCOVID, according to a new systematic review
· New funding will help advance a potential low-cost diagnostic test for myalgic encephalomyelitis (#ME)
· The SPEAR study group has proposed a potential Long COVID clinical trial with the company’s next-generation monoclonal antibody, VYD2311https://thesicktimes.org/2025/09/16/research-updates-september-16/
-
· An estimated 36% of people with a documented SARS-CoV-2 infection worldwide have experienced #LongCOVID, according to a new systematic review
· New funding will help advance a potential low-cost diagnostic test for myalgic encephalomyelitis (#ME)
· The SPEAR study group has proposed a potential Long COVID clinical trial with the company’s next-generation monoclonal antibody, VYD2311https://thesicktimes.org/2025/09/16/research-updates-september-16/
· Two recent studies found limitations of the drug Paxlovid for protection from #LongCOVID, contrasting prior studies that suggested the antiviral drug might help prevent the disease
· Long COVID may increase menstrual bleeding, according to a new survey study published in Nature Communications
· A new clinical trial is testing the supplement Mitoquinone in combination with “exercise rehabilitation” (which may be detrimental) for Long COVIDhttps://thesicktimes.org/2025/09/23/research-updates-september-23/
-
· Two recent studies found limitations of the drug Paxlovid for protection from #LongCOVID, contrasting prior studies that suggested the antiviral drug might help prevent the disease
· Long COVID may increase menstrual bleeding, according to a new survey study published in Nature Communications
· A new clinical trial is testing the supplement Mitoquinone in combination with “exercise rehabilitation” (which may be detrimental) for Long COVIDhttps://thesicktimes.org/2025/09/23/research-updates-september-23/
· Researchers in Spain assessed over 190,000 participants, found that #LongCOVID prevalence was three to 10 times higher in individuals with three or more reported infections
· A new RECOVER study published in JAMA found that olfactory dysfunction, or changes to sense of smell, occurred in people after SARS-CoV-2 infection
· A behavioral trial at Columbia University (LONG-CALM) is assessing a vague “mindfulness intervention” for Long COVIDhttps://thesicktimes.org/2025/09/30/research-updates-september-30/
-
· Researchers in Spain assessed over 190,000 participants, found that #LongCOVID prevalence was three to 10 times higher in individuals with three or more reported infections
· A new RECOVER study published in JAMA found that olfactory dysfunction, or changes to sense of smell, occurred in people after SARS-CoV-2 infection
· A behavioral trial at Columbia University (LONG-CALM) is assessing a vague “mindfulness intervention” for Long COVIDhttps://thesicktimes.org/2025/09/30/research-updates-september-30/
· A new study that found the risk of Long COVID doubled in children following SARS-C0V-2 reinfection made mainstream headlines this week
· Researchers in Japan may have found a potential biomarker and treatment target for cognitive dysfunction in #LongCOVID
· A new phase 1 clinical trial is currently recruiting to test the GLP-1 agonist drug Liraglutide for Long COVID, multiple sclerosis, and acute leukemia
Research updates, October 7 - The Sick Times
A new study that found the risk of Long COVID doubled in children following SARS-C0V-2 reinfection made mainstream headlines this week.
The Sick Times - Chronicling the Long Covid crisis (thesicktimes.org)
-
· A new study that found the risk of Long COVID doubled in children following SARS-C0V-2 reinfection made mainstream headlines this week
· Researchers in Japan may have found a potential biomarker and treatment target for cognitive dysfunction in #LongCOVID
· A new phase 1 clinical trial is currently recruiting to test the GLP-1 agonist drug Liraglutide for Long COVID, multiple sclerosis, and acute leukemia
Research updates, October 7 - The Sick Times
A new study that found the risk of Long COVID doubled in children following SARS-C0V-2 reinfection made mainstream headlines this week.
The Sick Times - Chronicling the Long Covid crisis (thesicktimes.org)
· A large electronic health records study found SARS-CoV-2 infection is associated with elevated risks of Human Papillomavirus (HPV)-related cancer
· A small study in the Journal of Translation Medicine found a potential blood test for myalgic encephalomyelitis (ME)
· Researchers have developed a device that may be able to accurately measure fibrinaloid microclots in children
Research updates, October 14 - The Sick Times
A large electronic health records study found SARS-CoV-2 infection is associated with elevated risks of Human Papillomavirus (HPV)-related cancer.
The Sick Times - Chronicling the Long Covid crisis (thesicktimes.org)
-
· A large electronic health records study found SARS-CoV-2 infection is associated with elevated risks of Human Papillomavirus (HPV)-related cancer
· A small study in the Journal of Translation Medicine found a potential blood test for myalgic encephalomyelitis (ME)
· Researchers have developed a device that may be able to accurately measure fibrinaloid microclots in children
Research updates, October 14 - The Sick Times
A large electronic health records study found SARS-CoV-2 infection is associated with elevated risks of Human Papillomavirus (HPV)-related cancer.
The Sick Times - Chronicling the Long Covid crisis (thesicktimes.org)
· A clinical trial for the anti-inflammatory drug Colchicine did not find the drug effective for #LongCOVID
· A white paper from the Patient-Led Research Collaborative assessed Long COVID in India
· Researchers recently critiqued the study design and conclusions of a controversial 2024 study on ME, which asserted that the disease was a result of altered “effort preference” and deconditioning
Research updates, October 21 - The Sick Times
A clinical trial for the anti-inflammatory drug Colchicine did not find the drug effective for Long COVID, according to a new study published in JAMA Internal Medicine. The randomized trial included 346 participants in India who took at least 0.5 milligrams once or twice per day, or a placebo, for 52 weeks.
The Sick Times - Chronicling the Long Covid crisis (thesicktimes.org)
-
· A clinical trial for the anti-inflammatory drug Colchicine did not find the drug effective for #LongCOVID
· A white paper from the Patient-Led Research Collaborative assessed Long COVID in India
· Researchers recently critiqued the study design and conclusions of a controversial 2024 study on ME, which asserted that the disease was a result of altered “effort preference” and deconditioning
Research updates, October 21 - The Sick Times
A clinical trial for the anti-inflammatory drug Colchicine did not find the drug effective for Long COVID, according to a new study published in JAMA Internal Medicine. The randomized trial included 346 participants in India who took at least 0.5 milligrams once or twice per day, or a placebo, for 52 weeks.
The Sick Times - Chronicling the Long Covid crisis (thesicktimes.org)
· A small mechanistic study in Frontiers in Immunology analyzed chronic inflammation in #COVID19.
· A recent paper found that low-dose rapamycin alleviated symptoms of fatigue and post-exertional malaise in people with #MECFS.
· A phase 2 clinical trial is recruiting in Boston, Massachusetts to test the drugs Pyridostigmine (Mestinon) and Low-Dose Naltrexone (LDN) for ME.
Research updates, October 28 - The Sick Times
A small mechanistic study in Frontiers in Immunology analyzed chronic inflammation in COVID-19. Researchers assessed over 70,000 blood cells from eight participants across different disease states.
The Sick Times - Chronicling the Long Covid crisis (thesicktimes.org)
-
· A small mechanistic study in Frontiers in Immunology analyzed chronic inflammation in #COVID19.
· A recent paper found that low-dose rapamycin alleviated symptoms of fatigue and post-exertional malaise in people with #MECFS.
· A phase 2 clinical trial is recruiting in Boston, Massachusetts to test the drugs Pyridostigmine (Mestinon) and Low-Dose Naltrexone (LDN) for ME.
Research updates, October 28 - The Sick Times
A small mechanistic study in Frontiers in Immunology analyzed chronic inflammation in COVID-19. Researchers assessed over 70,000 blood cells from eight participants across different disease states.
The Sick Times - Chronicling the Long Covid crisis (thesicktimes.org)
· The #German government is cutting millions of euros in #LongCOVID funding
· Large electronic cohort study from Sweden found that 1.4% of people with a documented #COVID19 case were officially diagnosed with Long COVID by medical providers
· Lidia Morawska, Australian scientist who alerted the world that SARS-CoV-2 was airborne, was recently recognized for her work with a prestigious science prize for “pioneering research about the air we breathe"
Research updates, November 4 - The Sick Times
The German government is cutting millions of euros in Long COVID funding, according to the German business newspaper Handelsblatt.
The Sick Times - Chronicling the Long Covid crisis (thesicktimes.org)
-
· The #German government is cutting millions of euros in #LongCOVID funding
· Large electronic cohort study from Sweden found that 1.4% of people with a documented #COVID19 case were officially diagnosed with Long COVID by medical providers
· Lidia Morawska, Australian scientist who alerted the world that SARS-CoV-2 was airborne, was recently recognized for her work with a prestigious science prize for “pioneering research about the air we breathe"
Research updates, November 4 - The Sick Times
The German government is cutting millions of euros in Long COVID funding, according to the German business newspaper Handelsblatt.
The Sick Times - Chronicling the Long Covid crisis (thesicktimes.org)
· The RECOVER-NEURO clinical trial found that “cognitive rehabilitation” failed in treating #LongCOVID
· Scientists are revealing more about microclots and Long COVID. A recent study in the Journal of Medical Virology found a strong association between microclots and net-like structures that some white blood cells (called neutrophils) release to attack pathogens
· A study about #MECFS was retracted by the journal Food Science and Nutrition
Research updates, November 11 - The Sick Times
The RECOVER-NEURO clinical trial found that “cognitive rehabilitation” failed in treating Long COVID. The National Institutes of Health (NIH) study included 328 people who underwent interventions of either online cognitive training (computer games), a cognitive rehabilitation program, or received electric currents on their heads.
The Sick Times - Chronicling the Long Covid crisis (thesicktimes.org)
-
· The RECOVER-NEURO clinical trial found that “cognitive rehabilitation” failed in treating #LongCOVID
· Scientists are revealing more about microclots and Long COVID. A recent study in the Journal of Medical Virology found a strong association between microclots and net-like structures that some white blood cells (called neutrophils) release to attack pathogens
· A study about #MECFS was retracted by the journal Food Science and Nutrition
Research updates, November 11 - The Sick Times
The RECOVER-NEURO clinical trial found that “cognitive rehabilitation” failed in treating Long COVID. The National Institutes of Health (NIH) study included 328 people who underwent interventions of either online cognitive training (computer games), a cognitive rehabilitation program, or received electric currents on their heads.
The Sick Times - Chronicling the Long Covid crisis (thesicktimes.org)
· New mechanistic study in Science Translational Medicine identifies Epstein-Barr virus as a potential trigger of the autoimmune disease systemic #lupus erythematosus
· Michael Peluso of UCSF shared updates on two upcoming #LongCOVID trials:
- One potential trial called COMBAT-LC plans to test the combination of the monoclonal antibody Pemgarda with the antiviral Paxlovid
- The second trial INTERRUPT-LC will test the bladder cancer drug Anktiva
Research updates, November 18 - The Sick Times
A new mechanistic study in Science Translational Medicine identifies Epstein-Barr virus (EBV) as a potential trigger of the autoimmune disease systemic lupus erythematosus.
The Sick Times - Chronicling the Long Covid crisis (thesicktimes.org)
-
· New mechanistic study in Science Translational Medicine identifies Epstein-Barr virus as a potential trigger of the autoimmune disease systemic #lupus erythematosus
· Michael Peluso of UCSF shared updates on two upcoming #LongCOVID trials:
- One potential trial called COMBAT-LC plans to test the combination of the monoclonal antibody Pemgarda with the antiviral Paxlovid
- The second trial INTERRUPT-LC will test the bladder cancer drug Anktiva
Research updates, November 18 - The Sick Times
A new mechanistic study in Science Translational Medicine identifies Epstein-Barr virus (EBV) as a potential trigger of the autoimmune disease systemic lupus erythematosus.
The Sick Times - Chronicling the Long Covid crisis (thesicktimes.org)
· A review paper summarizes the vast global costs of #LongCOVID, it is estimated to have an average annual burden of at least $1 trillion globally per year
· A small study in Nature found SARS-CoV-2 in the organs of fetuses from people who were infected with the virus while pregnant
· The National Institutes of Health’s RECOVER-Treating Long COVID initiative released a draft of its protocol for the low-dose naltrexone trial for people ages 6-25
Research updates, November 25 - The Sick Times
A new review paper summarizes the vast global costs of Long COVID. Public health researcher Amit Bansal from the University of Bergen conducted an economic literature analysis and determined that Long COVID is estimated to have an average annual burden of at least $1 trillion globally each year.
The Sick Times - Chronicling the Long Covid crisis (thesicktimes.org)
-
· A review paper summarizes the vast global costs of #LongCOVID, it is estimated to have an average annual burden of at least $1 trillion globally per year
· A small study in Nature found SARS-CoV-2 in the organs of fetuses from people who were infected with the virus while pregnant
· The National Institutes of Health’s RECOVER-Treating Long COVID initiative released a draft of its protocol for the low-dose naltrexone trial for people ages 6-25
Research updates, November 25 - The Sick Times
A new review paper summarizes the vast global costs of Long COVID. Public health researcher Amit Bansal from the University of Bergen conducted an economic literature analysis and determined that Long COVID is estimated to have an average annual burden of at least $1 trillion globally each year.
The Sick Times - Chronicling the Long Covid crisis (thesicktimes.org)
· Large retrospective cohort study of over 18,000 births found infants exposed to #COVID19 during pregnancy were more likely to have adverse neurodevelopmental diagnoses as 3 years olds
· Another study has found that common diabetes drug metformin may help reduce risk of #LongCOVID
· NIH is recruiting for a small observational study to understand if people with neurological symptoms of Long COVID have inactive [?] remnants of SARS-CoV-2 in their bodies
Research updates, December 2 - The Sick Times
A large retrospective cohort study of over 18,000 live births found that infants exposed to SARS-CoV-2 infection during pregnancy were more likely to have adverse neurodevelopmental diagnoses by the time they were three years old.
The Sick Times - Chronicling the Long Covid crisis (thesicktimes.org)
-
· Large retrospective cohort study of over 18,000 births found infants exposed to #COVID19 during pregnancy were more likely to have adverse neurodevelopmental diagnoses as 3 years olds
· Another study has found that common diabetes drug metformin may help reduce risk of #LongCOVID
· NIH is recruiting for a small observational study to understand if people with neurological symptoms of Long COVID have inactive [?] remnants of SARS-CoV-2 in their bodies
Research updates, December 2 - The Sick Times
A large retrospective cohort study of over 18,000 live births found that infants exposed to SARS-CoV-2 infection during pregnancy were more likely to have adverse neurodevelopmental diagnoses by the time they were three years old.
The Sick Times - Chronicling the Long Covid crisis (thesicktimes.org)
· A new study in the International Journal of Infectious Diseases examines how #COVID19 impacts the immune system
· German government announced just over €500 million ($582 million USD) in funding for infection-associated diseases, including #LongCOVID & #MECFS
· A preprint using data from the DecodeME study found more than 250 genes associated with ME, 76 of which were shared with Long COVID
Research updates, December 9 - The Sick Times
A new study in the International Journal of Infectious Diseases examines how COVID-19 impacts the immune system.
The Sick Times - Chronicling the Long Covid crisis (thesicktimes.org)
-
· A new study in the International Journal of Infectious Diseases examines how #COVID19 impacts the immune system
· German government announced just over €500 million ($582 million USD) in funding for infection-associated diseases, including #LongCOVID & #MECFS
· A preprint using data from the DecodeME study found more than 250 genes associated with ME, 76 of which were shared with Long COVID
Research updates, December 9 - The Sick Times
A new study in the International Journal of Infectious Diseases examines how COVID-19 impacts the immune system.
The Sick Times - Chronicling the Long Covid crisis (thesicktimes.org)
· New study in Cureus found veterans diagnosed with #LongCOVID at 34% higher risk of visiting emergency department 6 months after infection
· “Our data demonstrate that [LC] is characterized by chronic inflammation, immune exhaustion, & metabolic dysregulation,” scientists conclud in new study published in Nature Immunology
· U.K. charity ME Association awards £1.1 million in funding to the Imperial College to study immunological profiles of LC & #MECFS
Research updates, December 16 - The Sick Times
A new observational study in Cureus found that veterans diagnosed with Long COVID had a 34% higher risk of visiting the emergency department (ED) six months following infection than those without Long COVID.
The Sick Times - Chronicling the Long Covid crisis (thesicktimes.org)
-
· New study in Cureus found veterans diagnosed with #LongCOVID at 34% higher risk of visiting emergency department 6 months after infection
· “Our data demonstrate that [LC] is characterized by chronic inflammation, immune exhaustion, & metabolic dysregulation,” scientists conclud in new study published in Nature Immunology
· U.K. charity ME Association awards £1.1 million in funding to the Imperial College to study immunological profiles of LC & #MECFS
Research updates, December 16 - The Sick Times
A new observational study in Cureus found that veterans diagnosed with Long COVID had a 34% higher risk of visiting the emergency department (ED) six months following infection than those without Long COVID.
The Sick Times - Chronicling the Long Covid crisis (thesicktimes.org)
· Two recent studies state that #LongCOVID is an occupational disease.
· Vanderbilt researchers are conducting an immune profiling study on people with Long COVID and postural orthostatic tachycardia syndrome (#POTS)
· A new phase two remote clinical trial was recently announced for myalgic encephalomyelitis (ME) #MECFS
Research updates, December 23 - The Sick Times
Two recent studies state that Long COVID is an occupational disease.
The Sick Times - Chronicling the Long Covid crisis (thesicktimes.org)
-
· Two recent studies state that #LongCOVID is an occupational disease.
· Vanderbilt researchers are conducting an immune profiling study on people with Long COVID and postural orthostatic tachycardia syndrome (#POTS)
· A new phase two remote clinical trial was recently announced for myalgic encephalomyelitis (ME) #MECFS
Research updates, December 23 - The Sick Times
Two recent studies state that Long COVID is an occupational disease.
The Sick Times - Chronicling the Long Covid crisis (thesicktimes.org)
· 43% of Latino people reported symptoms of #LongCOVID in a new survey study published in Journal of General Internal Medicine
· A case series for Long COVID using a combination of Paxlovid, valacyclovir (Valtrex) and celecoxib (Celebrex), was recently published in Frontiers of Immunology
· A new phase II clinical trial for Long COVID was recently announced in the Netherlands
Research updates, January 6 - The Sick Times
43% of Latino people reported symptoms of Long COVID in a new survey study published in Journal of General Internal Medicine. The survey included the responses of 1,500 participants in Washington state who had confirmed COVID-19 cases between 2020 and 2022.
The Sick Times - Chronicling the Long Covid crisis (thesicktimes.org)
-
· 43% of Latino people reported symptoms of #LongCOVID in a new survey study published in Journal of General Internal Medicine
· A case series for Long COVID using a combination of Paxlovid, valacyclovir (Valtrex) and celecoxib (Celebrex), was recently published in Frontiers of Immunology
· A new phase II clinical trial for Long COVID was recently announced in the Netherlands
Research updates, January 6 - The Sick Times
43% of Latino people reported symptoms of Long COVID in a new survey study published in Journal of General Internal Medicine. The survey included the responses of 1,500 participants in Washington state who had confirmed COVID-19 cases between 2020 and 2022.
The Sick Times - Chronicling the Long Covid crisis (thesicktimes.org)
· A large, electronic health records study published in JAMA Internal Medicine estimated that over 100,000 Americans died each year between 2022 and 2024 from #COVID19
· A new study published in Molecular & Cellular Proteomics found further evidence of abnormalities in post-exertional malaise #PEM
· A small phase two clinical trial is testing #Ketamine for #LongCOVID fatigue and cognitive function
Research updates, January 13 - The Sick Times
A large, electronic health records study published in JAMA Internal Medicine estimated that over 100,000 Americans died each year between 2022 and 2024 from COVID-19.
The Sick Times - Chronicling the Long Covid crisis (thesicktimes.org)
-
· A large, electronic health records study published in JAMA Internal Medicine estimated that over 100,000 Americans died each year between 2022 and 2024 from #COVID19
· A new study published in Molecular & Cellular Proteomics found further evidence of abnormalities in post-exertional malaise #PEM
· A small phase two clinical trial is testing #Ketamine for #LongCOVID fatigue and cognitive function
Research updates, January 13 - The Sick Times
A large, electronic health records study published in JAMA Internal Medicine estimated that over 100,000 Americans died each year between 2022 and 2024 from COVID-19.
The Sick Times - Chronicling the Long Covid crisis (thesicktimes.org)
· A new study in eBioMedicine found neurological #LongCOVID symptoms were associated with increased pTau-181 levels, a marker of brain inflammation tied to Alzheimer’s disease
· A new “state-of-the-art” review on #POTS highlighted that the multisystemic condition is disabling, causes societal & economic withdrawal
· A phase II clinical trial testing efficacy & safety Uplizna (Inebilizumab) in LC & #MECFS recently announced by German Ministry of Research
Research updates, January 20 - The Sick Times
A new study in eBioMedicine found neurological Long COVID symptoms were associated with increased pTau-181 levels, a marker of brain inflammation that has been tied to Alzheimer's disease.
The Sick Times - Chronicling the Long Covid crisis (thesicktimes.org)
-
· A new study in eBioMedicine found neurological #LongCOVID symptoms were associated with increased pTau-181 levels, a marker of brain inflammation tied to Alzheimer’s disease
· A new “state-of-the-art” review on #POTS highlighted that the multisystemic condition is disabling, causes societal & economic withdrawal
· A phase II clinical trial testing efficacy & safety Uplizna (Inebilizumab) in LC & #MECFS recently announced by German Ministry of Research
Research updates, January 20 - The Sick Times
A new study in eBioMedicine found neurological Long COVID symptoms were associated with increased pTau-181 levels, a marker of brain inflammation that has been tied to Alzheimer's disease.
The Sick Times - Chronicling the Long Covid crisis (thesicktimes.org)
· A large prospective cohort study published in Infectious Diseases found that a majority of people with #LongCOVID did not recover
· Some researchers in Australia are getting a small boost in Long COVID funding
· The biotech company Invivyd is advancing research of a #COVID19 monoclonal antibody called VYD2311, designed to improve upon the currently-available Pemgarda
Research updates, January 27 - The Sick Times
A large prospective cohort study published in Infectious Diseases found that a majority of people with Long COVID did not recover.
The Sick Times - Chronicling the Long Covid crisis (thesicktimes.org)
-
· A large prospective cohort study published in Infectious Diseases found that a majority of people with #LongCOVID did not recover
· Some researchers in Australia are getting a small boost in Long COVID funding
· The biotech company Invivyd is advancing research of a #COVID19 monoclonal antibody called VYD2311, designed to improve upon the currently-available Pemgarda
Research updates, January 27 - The Sick Times
A large prospective cohort study published in Infectious Diseases found that a majority of people with Long COVID did not recover.
The Sick Times - Chronicling the Long Covid crisis (thesicktimes.org)
· The Food and Drug Administration (FDA) has granted expanded access to the stem cell infusion RegeneCyte for #LongCOVID
· Long COVID isn’t being consistently captured around the world due to differences in sociological factors, diagnostic tools, and healthcare access
· A phase two trial for Long COVID-associated postural orthostatic tachycardia syndrome (#POTS) is testing a product called 2-hydroxybenzylamine (2-HOBA)
Research updates, February 3 - The Sick Times
The Food and Drug Administration (FDA) has granted expanded access to the stem cell infusion RegeneCyte for Long COVID.
The Sick Times - Chronicling the Long Covid crisis (thesicktimes.org)
